Camurus AB (publ) (CAMX.ST)
SEK 632.0
(1.77%)
SEK 632.0
(1.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 414.81 Million SEK | 33.46% |
| 2022 | 310.81 Million SEK | 33.4% |
| 2021 | 232.98 Million SEK | 18.47% |
| 2020 | 196.65 Million SEK | 40.06% |
| 2019 | 140.41 Million SEK | 24.92% |
| 2018 | 112.4 Million SEK | 23.61% |
| 2017 | 90.93 Million SEK | 20.67% |
| 2016 | 75.35 Million SEK | -57.13% |
| 2015 | 175.79 Million SEK | 108.75% |
| 2014 | 84.21 Million SEK | 36.69% |
| 2013 | 61.6 Million SEK | 258.3% |
| 2012 | 17.19 Million SEK | -77.46% |
| 2011 | 76.3 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 415.06 Million SEK | 0.06% |
| 2024 Q2 | 503.72 Million SEK | 21.36% |
| 2023 Q3 | 353.35 Million SEK | -9.79% |
| 2023 FY | 414.81 Million SEK | 33.46% |
| 2023 Q1 | 288.58 Million SEK | -7.15% |
| 2023 Q4 | 414.81 Million SEK | 17.4% |
| 2023 Q2 | 391.67 Million SEK | 35.72% |
| 2022 Q1 | 238.9 Million SEK | 2.54% |
| 2022 FY | 310.81 Million SEK | 33.4% |
| 2022 Q4 | 310.81 Million SEK | 17.24% |
| 2022 Q3 | 265.1 Million SEK | 8.04% |
| 2022 Q2 | 245.37 Million SEK | 2.71% |
| 2021 Q4 | 232.98 Million SEK | 6.61% |
| 2021 Q1 | 202.02 Million SEK | 2.73% |
| 2021 Q2 | 226.05 Million SEK | 11.89% |
| 2021 Q3 | 218.53 Million SEK | -3.32% |
| 2021 FY | 232.98 Million SEK | 18.47% |
| 2020 FY | 196.65 Million SEK | 40.06% |
| 2020 Q2 | 173.76 Million SEK | 8.72% |
| 2020 Q3 | 165.96 Million SEK | -4.49% |
| 2020 Q4 | 196.65 Million SEK | 18.49% |
| 2020 Q1 | 159.82 Million SEK | 13.83% |
| 2019 FY | 140.41 Million SEK | 24.92% |
| 2019 Q4 | 140.41 Million SEK | -4.79% |
| 2019 Q3 | 147.47 Million SEK | 1.93% |
| 2019 Q2 | 144.68 Million SEK | 1.75% |
| 2019 Q1 | 142.19 Million SEK | 26.51% |
| 2018 Q3 | 101.9 Million SEK | -4.89% |
| 2018 Q2 | 107.14 Million SEK | 23.16% |
| 2018 Q1 | 86.99 Million SEK | -4.33% |
| 2018 FY | 112.4 Million SEK | 23.61% |
| 2018 Q4 | 112.4 Million SEK | 10.3% |
| 2017 Q3 | 83.57 Million SEK | 2.49% |
| 2017 FY | 90.93 Million SEK | 20.67% |
| 2017 Q1 | 73.42 Million SEK | -2.57% |
| 2017 Q4 | 90.93 Million SEK | 8.81% |
| 2017 Q2 | 81.54 Million SEK | 11.06% |
| 2016 FY | 75.35 Million SEK | -57.13% |
| 2016 Q4 | 75.35 Million SEK | 31.15% |
| 2016 Q3 | 57.46 Million SEK | 1.84% |
| 2016 Q2 | 56.42 Million SEK | 2.51% |
| 2016 Q1 | 55.04 Million SEK | -68.69% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q4 | 175.79 Million SEK | 64.05% |
| 2015 FY | 175.79 Million SEK | 108.75% |
| 2015 Q3 | 107.15 Million SEK | 0.0% |
| 2014 Q4 | 84.21 Million SEK | 0.0% |
| 2014 FY | 84.21 Million SEK | 36.69% |
| 2013 FY | 61.6 Million SEK | 258.3% |
| 2012 FY | 17.19 Million SEK | -77.46% |
| 2011 FY | 76.3 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Active Biotech AB (publ) | 13.4 Million SEK | -2995.664% |
| Biovica International AB (publ) | 34.76 Million SEK | -1093.14% |
| Cantargia AB (publ) | 54.97 Million SEK | -654.628% |
| CombiGene AB (publ) | 4.15 Million SEK | -9881.21% |
| Cyxone AB (publ) | 4.69 Million SEK | -8737.218% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -5613.76% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -2912.139% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -3012.387% |
| Fluicell AB (publ) | 8.91 Million SEK | -4553.045% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -798.265% |
| Mendus AB (publ) | 51.22 Million SEK | -709.798% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -2064.574% |
| I-Tech AB | 16.2 Million SEK | -2459.821% |
| Intervacc AB (publ) | 21.68 Million SEK | -1813.372% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -7942.245% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -234.588% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -17484.527% |
| OncoZenge AB (publ) | 1.69 Million SEK | -24315.48% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -1098.795% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 13.969% |
| Lipum AB (publ) | 7.53 Million SEK | -5403.038% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -289.154% |
| Ziccum AB (publ) | 6.38 Million SEK | -6393.723% |
| BioArctic AB (publ) | 139.5 Million SEK | -197.355% |
| Genovis AB (publ.) | 98.04 Million SEK | -323.082% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -576.074% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -2473.798% |
| Aptahem AB (publ) | 8.99 Million SEK | -4510.213% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -915.245% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -477.34% |
| Kancera AB (publ) | 17.97 Million SEK | -2207.37% |
| Saniona AB (publ) | 86.08 Million SEK | -381.883% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -3455.185% |
| AcouSort AB (publ) | 10.37 Million SEK | -3897.1% |
| Xintela AB (publ) | 14.01 Million SEK | -2859.822% |
| Abliva AB (publ) | 16.78 Million SEK | -2371.956% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -3485.608% |
| Amniotics AB (publ) | 10.54 Million SEK | -3833.052% |
| 2cureX AB (publ) | 2.93 Million SEK | -14033.526% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -9272.323% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 73.507% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 65.021% |
| Biosergen AB | 5.08 Million SEK | -8057.699% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -1453.164% |
| Corline Biomedical AB | 6.78 Million SEK | -6010.163% |
| NextCell Pharma AB | 13.68 Million SEK | -2930.297% |
| Nanologica AB (publ) | 79.32 Million SEK | -422.923% |
| LIDDS AB (publ) | 3.75 Million SEK | -10944.169% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | -93.299% |
| BioInvent International AB (publ) | 90.45 Million SEK | -358.602% |
| SynAct Pharma AB | 51.83 Million SEK | -700.284% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -5118.505% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -7885.054% |
| Alzinova AB (publ) | 9.33 Million SEK | -4345.601% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -3155.014% |
| Oncopeptides AB (publ) | 181.59 Million SEK | -128.427% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -23022.575% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -2142.992% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -10708.207% |
| Simris Alg AB (publ) | 148.93 Million SEK | -178.518% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -483.283% |